| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 121-130, 2019 | 2322 | 2019 |
| Acute and chronic effect of insulin on leptin production in humans: studies in vivo and in vitro JW Kolaczynski, MR Nyce, RV Considine, G Boden, JJ Nolan, R Henry, ... Diabetes 45 (5), 699-701, 1996 | 1145 | 1996 |
| Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease S Mudaliar, RR Henry, AJ Sanyal, L Morrow, HU Marschall, M Kipnes, ... Gastroenterology 145 (3), 574-582. e1, 2013 | 1052 | 2013 |
| Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial FL Greenway, K Fujioka, RA Plodkowski, S Mudaliar, M Guttadauria, ... The Lancet 376 (9741), 595-605, 2010 | 1018 | 2010 |
| Pioglitazone for diabetes prevention in impaired glucose tolerance RA DeFronzo, D Tripathy, DC Schwenke, MA Banerji, GA Bray, ... New England Journal of Medicine 364 (12), 1104-1115, 2011 | 918 | 2011 |
| Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis S Mudaliar, S Alloju, RR Henry Diabetes care 39 (7), 1115-1122, 2016 | 646 | 2016 |
| Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 131-138, 2019 | 543 | 2019 |
| Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. SE Nikoulina, TP Ciaraldi, S Mudaliar, P Mohideen, L Carter, RR Henry Diabetes 49 (2), 263-271, 2000 | 485 | 2000 |
| Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study P Raskin, BW Bode, JB Marks, IB Hirsch, RL Weinstein, JB McGill, ... Diabetes care 26 (9), 2598-2603, 2003 | 359 | 2003 |
| New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers S Mudaliar, RR Henry Annual review of medicine 52 (1), 239-257, 2001 | 354 | 2001 |
| Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. SR Mudaliar, FA Lindberg, M Joyce, P Beerdsen, P Strange, A Lin, ... Diabetes care 22 (9), 1501-1506, 1999 | 352 | 1999 |
| Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy SA Phillips, TP Ciaraldi, APS Kong, R Bandukwala, V Aroda, L Carter, ... Diabetes 52 (3), 667-674, 2003 | 343 | 2003 |
| Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized … D Polidori, S Sha, S Mudaliar, TP Ciaraldi, A Ghosh, N Vaccaro, K Farrell, ... Diabetes care 36 (8), 2154-2161, 2013 | 339 | 2013 |
| Human VEGF gene expression in skeletal muscle: effect of acute normoxic and hypoxic exercise RS Richardson, H Wagner, SRD Mudaliar, R Henry, EA Noyszewski, ... American Journal of Physiology-Heart and Circulatory Physiology 277 (6 …, 1999 | 293 | 1999 |
| Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II … RR Henry, AM Lincoff, S Mudaliar, M Rabbia, C Chognot, M Herz The Lancet 374 (9684), 126-135, 2009 | 270 | 2009 |
| Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes NV Chu, APS Kong, DD Kim, D Armstrong, S Baxi, R Deutsch, M Caulfield, ... Diabetes Care 25 (3), 542-549, 2002 | 261 | 2002 |
| Sodium–glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside S Mudaliar, D Polidori, B Zambrowicz, RR Henry Diabetes care 38 (12), 2344-2353, 2015 | 258 | 2015 |
| Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study RR Henry, J Rosenstock, S Edelman, S Mudaliar, AG Chalamandaris, ... Diabetes care 38 (3), 412-419, 2015 | 258 | 2015 |
| Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle SE Nikoulina, TP Ciaraldi, S Mudaliar, L Carter, K Johnson, RR Henry Diabetes 51 (7), 2190-2198, 2002 | 244 | 2002 |
| Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action M Loviscach, N Rehman, L Carter, S Mudaliar, P Mohadeen, TP Ciaraldi, ... Diabetologia 43, 304-311, 2000 | 236 | 2000 |
devjit tripathyuniversity of texas health science center在 uthscsa.edu 的电子邮件经过验证
